As of 2026-05-27, the Relative Valuation of Avidity Biosciences Inc (RNA) is (54.97) USD. This relative valuation is based on P/E multiples. With the latest stock price at 13.06 USD, the upside of Avidity Biosciences Inc based on Relative Valuation is -520.9%.
The range of the Relative Valuation is (49.99) - (58.09) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.9x - 20.1x | 18.0x |
| Forward P/E multiples | 17.3x - 20.5x | 20.0x |
| Fair Price | (49.99) - (58.09) | (54.97) |
| Upside | -482.8% - -544.8% | -520.9% |
| Date | P/E |
| 2026-05-26 | -4.51 |
| 2026-05-22 | -4.52 |
| 2026-05-21 | -4.51 |
| 2026-05-20 | -4.40 |
| 2026-05-19 | -4.48 |
| 2026-05-18 | -4.48 |
| 2026-05-15 | -4.57 |
| 2026-05-14 | -4.59 |
| 2026-05-13 | -4.60 |
| 2026-05-12 | -4.54 |
| 2026-05-11 | -4.58 |
| 2026-05-08 | -4.52 |
| 2026-05-07 | -4.48 |
| 2026-05-06 | -4.52 |
| 2026-05-05 | -4.46 |
| 2026-05-04 | -4.45 |
| 2026-05-01 | -4.64 |
| 2026-04-30 | -4.41 |
| 2026-04-29 | -4.49 |
| 2026-04-28 | -4.34 |
| 2026-04-27 | -4.46 |
| 2026-04-24 | -4.66 |
| 2026-04-23 | -4.79 |
| 2026-04-22 | -4.72 |
| 2026-04-21 | -4.68 |
| 2026-04-20 | -4.94 |
| 2026-04-17 | -4.98 |
| 2026-04-16 | -4.85 |
| 2026-04-15 | -5.03 |
| 2026-04-14 | -4.85 |
| 2026-04-13 | -4.60 |
| 2026-04-10 | -4.39 |
| 2026-04-09 | -4.74 |
| 2026-04-08 | -4.74 |
| 2026-04-07 | -4.84 |
| 2026-04-06 | -4.73 |
| 2026-04-02 | -4.65 |
| 2026-04-01 | -4.66 |
| 2026-03-31 | -4.62 |
| 2026-03-30 | -4.68 |
| 2026-03-27 | -4.57 |
| 2026-03-26 | -4.53 |
| 2026-03-25 | -4.52 |
| 2026-03-24 | -4.56 |
| 2026-03-23 | -4.56 |
| 2026-03-20 | -4.54 |
| 2026-03-19 | -4.39 |
| 2026-03-18 | -4.26 |
| 2026-03-17 | -4.76 |
| 2026-03-16 | -4.77 |